Leveraging homologous recombination deficiency for sarcoma
We provide a personalized oncological approach to potentially improve the treatment of sarcoma patients. We encourage the evaluation of gene expression signatures to enhance the identification of patients who might benefit from DDR-based therapies.
Authors
- Chantal Pauli (ORCID: https://orcid.org/0000-0001-9621-8511)
- Lara Planas‐Paz (ORCID: https://orcid.org/0000-0001-9603-9257)
Institutions
- University Hospital of Zurich (CH)
Publication Details
- Journal
- Die Pathologie
- Published
- 2024-11-01
- DOI
- https://doi.org/10.1007/s00292-024-01381-y
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Universität Zürich